Novel Disease-Modifying Drugs against Skin Fibrosis of Systemic Sclerosis
نویسندگان
چکیده
منابع مشابه
Hope for disease-modifying treatment of systemic sclerosis/scleroderma.
Systemic sclerosis (SSc) is a connective tissue disease of inner organs and skin. Its cutaneous manifestations are called scleroderma but the terms “systemic sclerosis” and “scleroderma” are sometimes used interchangeably (Fett, 2013). The American College of Rheumatology and the European League against Rheumatism have recently issued a consensus statement for the classification of SSc (van den...
متن کاملHigh frequency skin ultrasonography in systemic sclerosis
Background: Systemic sclerosis is an autoimmune connective tissue disorder which is characterised by cutaneous and internal organ fibrosis. Raynaud’s phenomenon is the earliest feature and may precede the onset of the disease by months to years. The heart, lungs, gastrointestinal tract, kidneys and other organs may be involved. Our aim was to evaluate skin thickness and echogenicity in systemic...
متن کاملcost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in iran.
background: disease-modifying drugs (dmds) are a significant expenditure for treating multiple sclerosis (ms). however, there is limited report on assessment of the cost-utility of dmds compared with symptom management in the presence of long-term data. this study aimed to assess the lifetime cost-utility from the iranian healthcare perspectives of 4dmds relative to symptom management alone in ...
متن کاملDisease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
With the development of effective therapies for multiple sclerosis (MS), therapeutic nihilism, which was so prevalent just 10 years ago, has given way to exuberance and optimism. The current mood is understandable because MS is such a devastating disease. Within 10 years of symptom onset, 50% of patients with MS are unable to carry out household and employment responsibilities; within 15 to 20 ...
متن کاملBiologic Disease-Modifying Antirheumatic Drugs
1. Distinguish between biologic DMARD use and nonbiologic DMARD use in the treatment of rheumatoid arthritis (RA). 2. Assess the differences between classes of biologic disease-modifying antirheumatic drug (DMARD) therapy. 3. Based on individual patient characteristics, construct a treatment and monitoring plan for a patient with RA and, when appropriate, include biologic DMARD therapy. 4. Just...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Trends in Immunotherapy
سال: 2020
ISSN: 2573-5985
DOI: 10.24294/ti.v4.i2.1050